SHC005V

Sigma-Aldrich

MISSION® pLKO.1-puro eGFP shRNA Control Transduction Particles

shRNA sequence targeting eGFP

Synonym(s):
MISSION TurboGFP Control Transduction Particles
NACRES:
NA.51
Pricing and availability is not currently available.

product line

MISSION®

concentration

≥1x106 VP/ml (via p24 assay)

application(s)

capture ELISA: 106 TU/mL using p24

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

General description

The MISSION eGFP shRNA Control Transduction Particles contain an shRNA sequence targeting eGFP (GenBank Accession No. pEGFP U55761). The eGFP shRNA Control Particles are useful as a positive knockdown control in experiments using cell lines expressing eGFP.
The eGFP shRNA Control Transduction Particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro-eGFP shRNA (Prod. No. SHC005). Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. In addition, the control transduction particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. 200 μl of 106 TU/ml (via p24 titering assay) lentiviral particles are provided as frozen stock.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit
sigma.com/shrna.

Application

To see more application data, protocols, vector maps visit sigma.com/shrna.

Legal Information

MISSION is a registered trademark of Sigma-Aldrich Co. LLC

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

UN 3245 9

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Marine Warnier et al.
Aging cell, 17(3), e12736-e12736 (2018-02-16)
Oncogenic signals lead to premature senescence in normal human cells causing a proliferation arrest and the elimination of these defective cells by immune cells. Oncogene-induced senescence (OIS) prevents aberrant cell division and tumor initiation. In order to identify new regulators...
Mariano J Alvarez et al.
Nature genetics, 50(7), 979-989 (2018-06-20)
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins...
Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.
Kikuchi K, Hettmer S, Aslam MI, et al.
PLoS Genetics, 10(1), e1004107-e1004107 (2014)
R Zufferey et al.
Journal of virology, 72(12), 9873-9880 (1998-11-13)
In vivo transduction of nondividing cells by human immunodeficiency virus type 1 (HIV-1)-based vectors results in transgene expression that is stable over several months. However, the use of HIV-1 vectors raises concerns about their safety. Here we describe a self-inactivating...
Ruth S Cruz Cosme et al.
Journal of virology, 83(7), 2839-2850 (2009-01-16)
Human cytomegalovirus (HCMV), a member of the beta subgroup of the family Herpesviridae, causes serious health problems worldwide. HCMV gene expression in host cells is a well-defined sequential process: immediate-early (IE) gene expression, early-gene expression, DNA replication, and late-gene expression....

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.